Current experimental human tissue-derived models for prostate cancer research
- PMID: 33247498
- DOI: 10.1111/iju.14441
Current experimental human tissue-derived models for prostate cancer research
Abstract
Scientists engaged in prostate cancer research have been conducting experiments using two-dimensional cultures of prostate cancer cell lines for decades. However, these experiments fail to reproduce and reflect the clinical course of individual patients with prostate cancer, or the molecular and genetic characteristics of prostate cancer, the basic requirement for most of the preclinical studies on prostate cancer. The use of human prostate cancer tissues in experiments has enabled the collection and verification of clinically relevant data, including chemical reactions, changes in proteins, and specific gene expression. Tissue recombination models have been employed for studying prostate development, the initiation and progression of prostate cancer, and the tumor microenvironment. Notably, the epithelial-stromal interaction, which might play a critical role in prostate cancer pathogenesis, can be reproduced in this model. Patient-derived xenograft models have been developed as powerful avatars comprising patient-derived prostate cancer tissues implanted in immunocompromised mice and could serve as a precision medicine approach for each prostate cancer patient. Spheroid and organoid assays, representative of modern three-dimensional cultures, can replicate the conditions in human prostate tumors and the prostate organ itself as a miniature model. Although an intact immune system against the tumor is missing from the models aimed at investigating immuno-oncological reagents in various malignancies, all these experimental models can help researchers in developing new drugs and selecting appropriate treatment strategies for prostate cancer patients.
Keywords: organoids; patient-derived xenograft models; prostate cancer; spheroids; three-dimensional culture; tissue recombination models.
© 2020 The Japanese Urological Association.
Similar articles
-
Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.Int J Mol Sci. 2024 Jan 16;25(2):1093. doi: 10.3390/ijms25021093. Int J Mol Sci. 2024. PMID: 38256166 Free PMC article. Review.
-
Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer.J Vis Exp. 2019 Jun 13;(148):10.3791/59710. doi: 10.3791/59710. J Vis Exp. 2019. PMID: 31259888 Free PMC article.
-
[Progress in prostate cancer study: 3D cell culture enables the ex vivo reproduction of tumor characteristics].Presse Med. 2017 Oct;46(10):954-965. doi: 10.1016/j.lpm.2017.06.014. Epub 2017 Sep 28. Presse Med. 2017. PMID: 28967525 French.
-
A synopsis of prostate organoid methodologies, applications, and limitations.Prostate. 2020 May;80(6):518-526. doi: 10.1002/pros.23966. Epub 2020 Feb 21. Prostate. 2020. PMID: 32084293 Review.
-
Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).Int J Oncol. 2022 May;60(5):52. doi: 10.3892/ijo.2022.5342. Epub 2022 Mar 24. Int J Oncol. 2022. PMID: 35322860 Review.
Cited by
-
The anti-inflammatory properties of the methanolic extract of Cucumis melo Linn. against prostate enlargement in Wistar rats.Saudi J Biol Sci. 2022 Sep;29(9):103396. doi: 10.1016/j.sjbs.2022.103396. Epub 2022 Jul 25. Saudi J Biol Sci. 2022. PMID: 35942162 Free PMC article.
-
Narrative Review of Patient Cancer Tissue-Derived Zebrafish Xenograft Models for Evaluating Drug Sensitivity as an Avatar Model for Clinical Application.Cancer Med. 2025 Jul;14(13):e70942. doi: 10.1002/cam4.70942. Cancer Med. 2025. PMID: 40567026 Free PMC article. Review.
-
Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.Mol Cancer. 2021 Sep 29;20(1):125. doi: 10.1186/s12943-021-01426-3. Mol Cancer. 2021. PMID: 34587953 Free PMC article. Review.
-
Advances in the application of colorectal cancer organoids in precision medicine.Front Oncol. 2024 Dec 3;14:1506606. doi: 10.3389/fonc.2024.1506606. eCollection 2024. Front Oncol. 2024. PMID: 39697234 Free PMC article. Review.
-
Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer.Front Cell Dev Biol. 2021 Feb 9;9:623809. doi: 10.3389/fcell.2021.623809. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33634124 Free PMC article. Review.
References
-
- Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am. J. Mens Health 2018; 12: 1807-23.
-
- Horoszewicz JS, Leong SS, Chu TM et al. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 1980; 37: 115-32.
-
- Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 1979; 17: 16-23.
-
- Sramkoski RM, Pretlow TG 2nd, Giaconia JM et al. A new human prostate carcinoma cell line, 22Rv1. Vitro Cell. Dev. Biol. Anim. 1999; 35: 403-9.
-
- Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 1978; 21: 274-81.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical